Open AccessFollow‐Up Studies On Preterm Infants After Maternal β‐Receptor Agonist Treatment
Author(s) -
Svenningsen Niels W.
Publication year - 1982
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348209155349
Subject(s) - medicine , agonist , hypoglycemia , incidence (geometry) , obstetrics , pregnancy , pediatrics , receptor , endocrinology , diabetes mellitus , physics , biology , optics , genetics
. A review of the existing literature regarding the outcome of infants delivered preterm after antenatal β‐receptor agonist treatment of the mother is presented. Some investigators have reported an increased rate of neonatal and long‐term hazards, while others have not found a higher incidence of such complications after antenatal β‐receptor treatment. In our own material of 54 preterm survivors with follow‐up up to 2 years of age, we found a modest rise in postnatal hypoglycemia rate but no other short‐term or long‐term sequelae. Postnatal monitoring of blood glucose and cardiovascular function is warranted at preterm deliveries after antenatal β‐receptor agonist treatment.